FDA approves new drugs for pediatric type 2 diabetes treatment.
TL;DR Summary
The FDA has approved Jardiance and Synjardy as new oral therapies to treat pediatric type 2 diabetes in children aged 10 and older. Type 2 diabetes is a chronic and progressive condition that affects the body's ability to use insulin normally, leading to high levels of glucose in the blood. Empagliflozin, the active ingredient in Jardiance and Synjardy, works by increasing the excretion of glucose in the urine. The incidence of type 2 diabetes in children is expected to continue increasing, and these approvals provide much-needed additional treatment options for children with type 2 diabetes.
- FDA Approves New Class of Medicines to Treat Pediatric Type 2 Diabetes FDA.gov
- US FDA approves Eli Lilly-Boehringer's diabetes drugs for children AOL
- Empagliflozin, Empagliflozin Plus Metformin for Pediatric Type 2 Diabetes Approved by FDA Drug Topics
- Lilly and Boehringer Drugs Approved as New Options for Type 2 Diabetes in Kids BioSpace
- FDA OKs Empagliflozin for Children With Type 2 Diabetes Medscape
Reading Insights
Total Reads
0
Unique Readers
1
Time Saved
4 min
vs 5 min read
Condensed
90%
927 → 95 words
Want the full story? Read the original article
Read on FDA.gov